Implementing HRD Testing in Routine Clinical Practice on Patients with Primary High-Grade Advanced Ovarian Cancer
Personalised treatment of ovarian cancer is the preferred and seemingly most effective course of management. With the development of PARP inhibitors this becomes available for those women who have a genetic mutation (HRD), which limits DNA, repair.
It is now possible to screen ovarian cancer patients for the presence of HRD either directly or indirectly via the BRCA status. This small review of 163 women showed 44% to be HRD, with only 12% being BRCA positive.
There are however difficulties in direct HRD testing with 27 patients having insufficient tumor load for HRD testing and the median delay for results was 37 days. HRD testing will not replace germ line BRCA screen but does increase the numbers of women who will benefit from personalised care.
No comments:
Post a Comment